- CHF 500 million investment for large-scale drug product facility in Stein
- Completion expected in 2026
- Facility to leverage existing infrastructure and talent
- Focus on sustainable construction with photovoltaic roof
Investment and Timeline
Lonza has announced a CHF 500 million investment to construct a large-scale commercial drug product fill and finish facility in Stein, Switzerland. The project is expected to be completed by 2026.
Integrated End-to-End Solution
The new facility will enable Lonza to offer a complete and integrated end-to-end solution for commercial drug product manufacturing. This expansion aims to meet the sustained customer demand and enhance the company's market share.
Strategic Location
The facility will be built on the same campus as Lonza’s current clinical drug product facility in Stein, allowing the company to leverage existing infrastructure, capabilities, and talent.
Sustainability Focus
The construction will incorporate the latest developments in sustainable building practices, including a photovoltaic roof to reduce carbon footprint and promote responsible energy use.
